Susquehanna International Group
LPCN icon

Susquehanna International Group’s Lipocine LPCN Stock Holding History

Susquehanna International Group’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-935
Closed -$7K – 13131
2022
Q3 		$7K Sell
935
-524
-36% -$5.85K ﹤0.01% 12838
2022
Q2 		$20K Sell
1,459
-676
-32% -$10.5K ﹤0.01% 12365
2022
Q1 		$50K Sell
2,135
-4,147
-66% -$86.8K ﹤0.01% 12315
2021
Q4 		$106K Buy
6,282
+3,953
+170% +$73.4K ﹤0.01% 12107
2021
Q3 		$43K Sell
2,329
-1,706
-42% -$37.6K ﹤0.01% 12397
2021
Q2 		$96K Sell
4,035
-13,747
-77% -$323K ﹤0.01% 12113
2021
Q1 		$456K Buy
17,782
+16,935
+1,999% +$489K ﹤0.01% 9698
2020
Q4 		$20K Sell
847
-4,924
-85% -$119K ﹤0.01% 10882
2020
Q3 		$138K Buy
+5,771
New +$153K ﹤0.01% 9739
2018
Q1 		– Sell
-788
Closed -$46K – 9802
2017
Q4 		$46K Buy
+788
New +$49K ﹤0.01% 8929
2016
Q4 		– Sell
-1,759
Closed -$133K – 9889
2016
Q3 		$133K Sell
1,759
-6,759
-79% -$419K ﹤0.01% 7826
2016
Q2 		$440K Buy
8,518
+7,689
+928% +$1.19M ﹤0.01% 6342
2016
Q1 		$143K Buy
+829
New +$141K ﹤0.01% 8242

Other funds holding LPCN

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $318M AUM
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Susquehanna International Group's LPCN Position: Q1 2026 in Review

Susquehanna International Group reduced its Lipocine (LPCN) stake by 0% in Q1 2026, selling an estimated $9 and leaving 24,908 shares worth $199K. The position accounts for ﹤0.01% of the portfolio, ranked #11717.

Susquehanna International Group first reported a position in LPCN in Q4 2015 and has held it in 31 quarters since. The position peaked at $700K in Q1 2016. 47 funds tracked by Wall St. Rank hold LPCN as of Q1 2026.

  • Susquehanna International Group held 24,908 shares of Lipocine worth $199K as of Q1 2026.
  • Susquehanna International Group sold 1 Lipocine share in Q1 2026, an estimated $9.
  • Lipocine made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #11717 holding.
  • Susquehanna International Group first reported a position in Lipocine in Q4 2015 and has held it in 31 quarters since.
  • Susquehanna International Group's Lipocine position peaked at $700K in Q1 2016.
  • 47 funds tracked by Wall St. Rank held Lipocine as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.